Targeting the human microbiome and its metabolite TMAO in cardiovascular prevention and therapy

Pharmacol Ther. 2020 Sep:213:107584. doi: 10.1016/j.pharmthera.2020.107584. Epub 2020 May 22.

Abstract

The human gut microbiota is the most important active part of the intestinal micro-ecosystem. Lifestyle modification, drug intake and nutrition have an impact on the composition of the gut microbiota and its metabolites. This review focuses on the effects of changes in the gut microbiota as well as the important metabolite Trimethylamine-N-oxide (TMAO). Furthermore, relevant therapeutic options to target the human microbiome in patients with cardiovascular disease are presented.

Keywords: MACCE; Microbiome; Myocardial infarction; Platelet aggregation; TMAO.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / microbiology
  • Cardiovascular Diseases / prevention & control*
  • Cardiovascular Diseases / therapy
  • Gastrointestinal Microbiome / physiology*
  • Humans
  • Life Style
  • Methylamines / metabolism*
  • Microbiota / physiology

Substances

  • Methylamines
  • trimethyloxamine